| Name | Title | Contact Details |
|---|
Buy Sod/ SodStar Offers You the Most Solutions with 15+ Sensational Turf Varieties! With our widespread network of sod farms, covering thousands of acres, across NC, SC, TN, GA and VA, and a range of hardiness zones and soil types, Buy Sod grows more turfgrass varieties than any other sod grower in the Carolinas or Virginia. Our all-encompassing roster includes traditional cultivars for turf managers wishing to stick to the tried-and-true, as well as newer next-generation grasses, for those seeking improved performance and aesthetic characteristics. No matter what type of site you manage — golf course, sports field, lawn/landscape, commercial property, park, cemetery or roadside right-of-way — we have your best turfgrass solution. Buy Sods branded, high-performance varieties have been thoroughly tested in research trials, with proven qualities that deliver dependable results. And all of our cultivars are grown under rigorous certification protocols, ensuring the genetic purity and integrity of whichever turfgrass you select. Equally important, our advanced routing system fast-tracks your order for rapid delivery even on short notice. Upon delivery confirmation and routing, we email to you a delivery notification with the expected arrival time and a link to a GPS system where you can track exactly where your sod is in route. Nothing is more important to us than not only fulfilling your needs but also exceeding your expectations. Thats why Buy Sod is truly the Professionals Source for Superior Selections and World-Class Service.
About Kotak Mahindra Group: Established in 1985, the Kotak Mahindra Group is one of Indias leading financial services conglomerates. In February 2003, Kotak Mahindra Finance Ltd. (KMFL), the Groups flagship company, received a banking license from the Reserve Bank of India (RBI). With this, KMFL became the first non-banking finance company in India to become a bank – Kotak Mahindra Bank Limited. The consolidated balance sheet of Kotak Mahindra Group is over 1 lakh crore and the consolidated net worth of the Group stands at 13,943 crore (approx US$ 2.6 billion) as on September 30, 2012. The Group offers a wide range of financial services that encompass every sphere of life. From commercial banking, to stock broking, mutual funds, life insurance and investment banking, the Group caters to the diverse financial needs of individuals and the corporate sector. The Group has a wide distribution network through branches and franchisees across India, and international offices in London, New York, California, Dubai, Abu Dhabi, Bahrain, Mauritius and Singapore. For more information, please visit the companys website at http://www.kotak.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.